Skip to main content

New story in Health from Time: Moderna’s COVID-19 Vaccine Shows Promise, Generating Positive Immune Responses in an Early Study



Earlier today, the biotech company Moderna reported positive results from a phase 1 study of its experimental COVID-19 vaccine, which was was among the first to begin testing in healthy human volunteers in mid-March.

The study, led by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, involves 45 healthy people who received one of three different doses of the vaccine. According to Moderna, there are encouraging early signs that the shot generates antibodies against the COVID-19 virus, SARS-CoV-2, in levels that were similar to or higher than those seen in the plasma of people who recovered from infections.

The phase 1 study is actually not designed to measure effectiveness of the vaccine—it is is focused primarily on safety. Nevertheless, the hints of efficacy emerging from the trial are encouraging. The level of antibodies seen in the participants show that the vaccine can attract and awaken the body’s immune response to mount a defense against SARS-CoV-2. The data also hinted that the higher doses prompted stronger immune responses.

In addition, the company reports that in a preliminary analysis, antibodies from eight of the participants (four given the low dose and four given the medium dose) appeared to neutralize the virus in the lab.

In the phase 1 study, the participants were all healthy volunteers aged 18 to 55 years. Those in the low- and medium-dose groups received two doses about a month apart, in order to properly prime the immune system for the most robust response. People in the highest dose group received only one inoculation. The results will likely be analyzed and reported in a scientific publication in coming weeks.

Based on these results, the phase 2 study, which the Food and Drug Administration (FDA) has cleared, will enroll around 600 healthy volunteers, will include just two doses—one that is slightly higher than the lowest dose, as well as the medium dose, since these appear to be sufficient to generate a relatively strong immune response. The company expects those trials to begin in June, and may include those at higher risk of exposure to SARS-CoV-2, such as health care workers. Those studies will determine which dose will be tested in the final, phase 3 studies that could begin as early as July. Based on the urgent need for a vaccine against COVID-19, on May 12 the FDA gave Moderna’s vaccine fast track status, which would expedite the regulatory agency’s review process.

These findings, though still early, are a validation of Moderna’s technology, which veers from the traditional vaccine design that generally depend on snippets of viral proteins or inactivated virus to activate the immune system. Moderna’s vaccine is made of mRNA from the virus, the genetic material that codes for proteins; after inoculation, it can prompt the body’s immune cells to recognize it as foreign and launch attacks against it. The company has been developing mRNA vaccines against a number of other disease, including respiratory syncytial virus, Zika and influenza.

Popular posts from this blog

New story in Health from Time: COVID-19 Has Been ‘Apocalyptic’ for Public Transit. Will Congress Offer More Help?

While trying to get to work over the past few months, Brittany Williams, a Seattle home care worker, has often been passed by two or three buses before one stops to let her board. Buses in her area that once carried anywhere from about 50 to 100 passengers have been limited to between 12 and 18 to prevent overcrowding in response to coronavirus, and Williams’ commute, typically a half-hour ride, now takes more than double that time. Other Seattle transit riders have described budgeting as much as an extra hour per trip to account for the reduced capacity, eating into their time at work, school or with family. Even with the ridership limits in place, Williams, 34, doesn’t feel safe on public transit. Some passengers don’t wear face coverings, and bus drivers sometimes ignore capacity limits, she says. On one ride with her seven-year-old son, she decided to get off at a stop far from her home after a driver allowed a crowd of people to board. “It’s very trying. I’ll put...

New story in Health from Time: An At-Home Coronavirus Test May Be On the Way in the U.S.

As cases of COVID-19 continue to climb in the U.S. , there’s a new urgency to make sure there are as many tests as possible to diagnose people who have symptoms that might indicate an infection. Knowing if people are positive is important for guiding their next steps: self-isolation, avoiding contact with others, and, if their symptoms get worse, seeking medical care. To date, access to tests has been spotty at best across the country, and while more kits are now available than even a week ago , most are gene-based assays that take several days for commercial labs to process and produce results. That may change in about two months if the Food and Drug Administration (FDA) gives Emergency Use Authorization to the first blood-based COVID-19 test in the U.S. Scanwell Health, an at-home test company based in California, licensed the rights to a test developed by Chinese company Innovita, which was used extensively at the height of country’s epidemic earlier this year. “The ...

New story in Health from Time: A Montana Care Home Refused Free COVID-19 Tests. Now, Nearly Every Resident Has Coronavirus

(BILLINGS, Mont.) — It was meant to be a last line of defense to protect the most vulnerable as the coronavirus spread across the United States : Montana officials offered free testing in May for staff and residents at assisted living and long-term care facilities. But not all of them followed through, according to state data, including a facility in Billings, Montana’s largest city, that cares for people with dementia and other memory problems. The virus has infected almost every resident and killed eight, accounting for almost a quarter of Montana’s 34 confirmed deaths. Thirty-six employees also have tested positive at the facility where 59 people lived before the deaths began. Read more: ‘It’s Getting Worse.’ Nursing Home Workers Confront Risks in Facilities Devastated by Coronavirus While Montana’s rates of confirmed infections and deaths are much lower than other parts of the country, the outbreak at Canyon Creek Memory Care illustrates that even the most simple an...